Distinguished by a novel chimeric gene segment design, the Trianni platform provides Takeda with easy access to a complete human antibody repertoire that has been optimized for the isolation of fully human therapeutics.
Trianni chairman and CEO Dr Matthias Wabl noted that the company is very pleased to see Takeda adopt the Trianni Mouse.
"With its many distinctive features, most notably a full repertoire expressed from chemically synthesized gene segments, we are confident the platform will prove highly productive for Takeda," Dr Wabl added.
Takeda pharmaceutical research division general manager Dr Tetsuyuki Maruyama noted the company is excited to add Trianni’s transgenic mice to Takeda’s repertoire of platform technologies for the generation of therapeutic antibodies.
"Takeda has a growing biologics pipeline and the Trianni Mouse is a natural addition to enhance our ongoing research capabilities in the area," Dr Maruyama added.